Poseida Therapeutics Announces Appointment Of Mark Gergen As Executive Chairman; Kristin Yarema Appointed As President And CEO; Each Expected To Be Effective Jan. 1, 2024
Portfolio Pulse from Benzinga Newsdesk
Poseida Therapeutics has announced the appointment of Mark Gergen as Executive Chairman and Kristin Yarema as President and CEO, effective from January 1, 2024. Yarema is currently the President of Cell Therapy at Poseida.
October 09, 2023 | 8:33 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Poseida Therapeutics (PSTX) has announced leadership changes that will take effect from January 1, 2024. Mark Gergen will become Executive Chairman and Kristin Yarema will be appointed as President and CEO.
Leadership changes can have a significant impact on a company's strategy and operations. However, as these changes are not due to take effect until 2024, the immediate impact on the stock price is likely to be neutral. The long-term impact will depend on how effectively the new leadership can execute the company's strategy.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100